Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Supernus Pharmaceuticals stock
Learn how to easily invest in Supernus Pharmaceuticals stock.
Supernus Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Supernus Pharmaceuticals shares (SUPN) are listed on the NASDAQ and all prices are listed in US Dollars. Supernus Pharmaceuticals employs 575 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Supernus Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SUPN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Supernus Pharmaceuticals stock price (NASDAQ: SUPN)Use our graph to track the performance of SUPN stocks over time.
Supernus Pharmaceuticals shares at a glance
|Latest market close||$29.35|
|52-week range||$23.15 - $34.50|
|50-day moving average||$27.98|
|200-day moving average||$29.69|
|Wall St. target price||$35.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$1.31|
Buy Supernus Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Supernus Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Supernus Pharmaceuticals price performance over time
|1 week (2022-06-24)||3.35%|
|1 month (2022-05-29)||N/A|
|3 months (2022-04-01)||-8.79%|
|6 months (2021-12-31)||0.65%|
|1 year (2021-07-02)||-3.36%|
|2 years (2020-07-02)||24.31%|
|3 years (2019-07-02)||32.79|
|5 years (2017-06-30)||43.1|
Is Supernus Pharmaceuticals stock undervalued or overvalued?
Valuing Supernus Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Supernus Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Supernus Pharmaceuticals's P/E ratio
Supernus Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Supernus Pharmaceuticals shares trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Supernus Pharmaceuticals's PEG ratio
Supernus Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Supernus Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Supernus Pharmaceuticals's EBITDA
Supernus Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $142.7 million.
The EBITDA is a measure of a Supernus Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Supernus Pharmaceuticals financials
|Revenue TTM||$601.3 million|
|Operating margin TTM||15.85%|
|Gross profit TTM||$504.7 million|
|Return on assets TTM||3.79%|
|Return on equity TTM||9.27%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
Supernus Pharmaceuticals share dividends
We're not expecting Supernus Pharmaceuticals to pay a dividend over the next 12 months.
Supernus Pharmaceuticals share price volatility
Over the last 12 months, Supernus Pharmaceuticals's shares have ranged in value from as little as $23.15 up to $34.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Supernus Pharmaceuticals's is 1.1252. This would suggest that Supernus Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Supernus Pharmaceuticals overview
Supernus Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Supernus Pharmaceuticals in the news
Supernus to Participate in the Jefferies Healthcare Conference
Supernus to Participate in the Jefferies Healthcare Conference
Frequently asked questionsWhat percentage of Supernus Pharmaceuticals is owned by insiders or institutions?
Currently 4.285% of Supernus Pharmaceuticals shares are held by insiders and 104.354% by institutions. How many people work for Supernus Pharmaceuticals?
Latest data suggests 575 work at Supernus Pharmaceuticals. When does the fiscal year end for Supernus Pharmaceuticals?
Supernus Pharmaceuticals's fiscal year ends in December. Where is Supernus Pharmaceuticals based?
Supernus Pharmaceuticals's address is: 9715 Key West Avenue, Rockville, MD, United States, 20850 What is Supernus Pharmaceuticals's ISIN number?
Supernus Pharmaceuticals's international securities identification number is: US8684591089 What is Supernus Pharmaceuticals's CUSIP number?
Supernus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 868459108
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert